{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:35:41Z","timestamp":1780608941521,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1016\/j.vaccine.2003.11.025","type":"journal-article","created":{"date-parts":[[2003,12,13]],"date-time":"2003-12-13T11:45:16Z","timestamp":1071315916000},"page":"812-817","source":"Crossref","is-referenced-by-count":22,"title":["Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis"],"prefix":"10.1016","volume":"22","author":[{"given":"Alan S","family":"Cross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Opal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Drabick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurba","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2003.11.025_BIB1","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJMoa022139","article-title":"The epidemiology of sepsis in the United States from 1979 through 2000","volume":"348","author":"Martin","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4049\/jimmunol.90.2.297","article-title":"The behavior Escherichia coli endotoxin (somatic antigen) during infectious arthritis","volume":"90","author":"Braude","year":"1960","journal-title":"J. Immunol."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB3","doi-asserted-by":"crossref","first-page":"601","DOI":"10.4049\/jimmunol.108.3.601","article-title":"Immunization with R mutants of S. minnesota. Part I. Protection against challenge with heterologous Gram-negative bacilli","volume":"108","author":"McCabe","year":"1972","journal-title":"J. Immunol."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4049\/jimmunol.111.2.433","article-title":"Treatment of E. coli and Klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-GAL epimerase-deficient mutant","volume":"111","author":"Ziegler","year":"1973","journal-title":"J. Immunol."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB5","first-page":"101","article-title":"Prevention of lethal Pseudomonas bacteremia with epimerase-deficient E. coli antiserum","volume":"88","author":"Ziegler","year":"1975","journal-title":"Trans. Assoc. Am. Physicians"},{"key":"10.1016\/j.vaccine.2003.11.025_BIB6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/infdis\/147.1.57","article-title":"Immunization with rough mutants of Salmonella minnesota. IV. Protection by antisera to O and rough antigens against endotoxin","volume":"147","author":"Johns","year":"1983","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB7","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJM198211113072001","article-title":"Treatment of Gram negative bacteremia and shock with human antiserum to a mutant Escherichia coli","volume":"307","author":"Ziegler","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB8","doi-asserted-by":"crossref","unstructured":"J5 Group. Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J Infect Dis 1992;165:695\u2013701.","DOI":"10.1093\/infdis\/165.4.695"},{"key":"10.1016\/j.vaccine.2003.11.025_BIB9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(85)90176-X","article-title":"Prevention of Gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid","volume":"2","author":"Baumgartner","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2003.11.025_BIB10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/infdis\/158.2.312","article-title":"Treat of Gram-negative septic shock human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial","volume":"158","author":"Calandra","year":"1988","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB11","doi-asserted-by":"crossref","unstructured":"The Intravenous Immunoglobulin Collaborative Study Group. Prophlactic intravenous immunoglobulin administration of standard immunoglobulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 1992;327:234\u201340.","DOI":"10.1056\/NEJM199207233270404"},{"key":"10.1016\/j.vaccine.2003.11.025_BIB12","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1172\/JCI111150","article-title":"Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core","volume":"72","author":"Pollack","year":"1983","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB13","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jama.274.2.172","article-title":"Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome","volume":"274","author":"Goldie","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2003.11.025_BIB14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/infdis\/133.1.37","article-title":"Effects of IgM and IgG antibody in patients with bacteremia due to Gram-negative bacilli","volume":"133","author":"Zinner","year":"1976","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00000658-199303000-00013","article-title":"Sequential anti-core glycolipid immunoglobulin antibody activities in patients with and without septic shock and their relation to outcome","volume":"217","author":"Nys","year":"1993","journal-title":"Ann. Surg."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB16","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/00003246-199109000-00003","article-title":"Treatment of Gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial","volume":"9","author":"Schedel","year":"1991","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB17","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3109\/00365548909021700","article-title":"Preliminary study on treatment of septic shock patients with antilipopolysaccharide IgG from blood donors","volume":"21","author":"Fomsgaard","year":"1989","journal-title":"Scand J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/IAI.17.1.16-20.1977","article-title":"Immunization with R mutants of Salmonella minnesota. III. Comparison of the protective effect of immunizaiton with lipid A and the Re mutant","volume":"17","author":"Bruins","year":"1977","journal-title":"Infect. Immun."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJM199102143240701","article-title":"Treatment of Gram-negative bacteremia in septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial","volume":"325","author":"Ziegler","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB20","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.266.8.1097","article-title":"A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis","volume":"266","author":"Greenman","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2003.11.025_BIB21","doi-asserted-by":"crossref","unstructured":"Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treeat sepsis and septic shock: a reassessment. Crit Care Med 1997;25:1095\u2013100.","DOI":"10.1097\/00003246-199707000-00001"},{"key":"10.1016\/j.vaccine.2003.11.025_BIB22","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/infdis\/159.6.1073","article-title":"Oral ciprofloxacin and anti-lipopolysaccharide monoclonal antibody protect leukopenic rats from lethal infection","volume":"159","author":"Collins","year":"1989","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB23","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/infdis\/170.3.622","article-title":"Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against Gram-negative bacterial sepsis","volume":"170","author":"Bhattacharjee","year":"1994","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB24","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/infdis\/173.5.1157","article-title":"A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc Chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against Gram-negative bacteremia","volume":"173","author":"Bhattacharjee","year":"1996","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB25","doi-asserted-by":"crossref","unstructured":"Cross AS, Opal SM, Palardy JE, Drabick JJ, Warren HS, Huber C, Cook P, Bhattacharjee AK. Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)\/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. Vaccine 2003;21:4576\u201388.","DOI":"10.1016\/S0264-410X(03)00483-3"},{"key":"10.1016\/j.vaccine.2003.11.025_BIB26","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/infdis\/158.5.1135","article-title":"Characterization of the human anti-body response to an Escherichia coli O111:B4 (J5) vaccine","volume":"158","author":"Schwartzer","year":"1988","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/314845","article-title":"Correlation of opsonophagocytosis and passive protection assay using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae","volume":"180","author":"Johnson","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3346\/jkms.1999.14.5.475","article-title":"Evaluation of antibody responses to pneumococcal vaccines with ELISA and opsonophagocytosis assay","volume":"14","author":"Kim","year":"1999","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1084\/jem.172.1.77","article-title":"Lipid IVA inhibits synthesis and release of tumor necrosis factor induced by lipopolysaccharide in human whole blood ex vivo","volume":"172","author":"Kovach","year":"1990","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB30","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1084\/jem.160.6.1656","article-title":"Priming of neutrophils for enhanced release of oxygen metabolites by bacterial lipopolysaccharide. Evidence for increased activity of the superoxide-producing enzyme","volume":"160","author":"Guthrie","year":"1984","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1084\/jem.177.1.89","article-title":"Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide","volume":"177","author":"Warren","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB32","unstructured":"Davis HL, Cooper CL, Morris ML, Elfer SM, Cameron DW, Heathcote J, CpG ODN is safe and highly effective in humans as an adjuvant in hepatitis B vaccines. Preliminary results of phase I trial with CpG 7909. In: Proceedings of the Third Annual Conference on Vaccines (Abstract S25); 2000."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00000658-199710000-00006","article-title":"Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection","volume":"226","author":"Lyons","year":"1997","journal-title":"Ann. Surg."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB34","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1046\/j.1365-2168.1998.00770.x","article-title":"Stimulation of inflammatory markers after blunt trauma","volume":"85","author":"Ginnoudis","year":"1998","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.vaccine.2003.11.025_BIB35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/clinids\/23.1.179","article-title":"Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an 8-valent Pseudomnas O-polysaccharide conjugate vaccine administered to acute trauma victims","volume":"23","author":"Campbell","year":"1996","journal-title":"Clin. Infect. Dis."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X03008223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X03008223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T16:46:41Z","timestamp":1682614001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X03008223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S0264410X03008223"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2003.11.025","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}